TFF Pharmaceuticals, Inc., an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company has a research collaboration with the University of Georgia's Center for Vaccines and Immunology (CVI), along with the University of Texas at Austin (UT Austin), to evaluate the immunogenicity of universal influenza vaccines; and cooperative research and development agreement with United States Army Medical Research Institute of Infectious Diseases for use of its thin film freezing technology platform. TFF Pharmaceuticals, Inc. also has a joint development and collaboration agreement with Augmenta Bioworks, Inc. to develop commercial products incorporating Augmenta's human-derived monoclonal antibodies for COVID-19 therapeutics. The company was founded in 2018 and is based in Austin, Texas.